Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genmab AS

This article was originally published in Start Up

Executive Summary

Medarex of Princeton, New Jersey was so pleased with the incentive package it found in Copenhagen, Denmark that it decided to spin out Genmab to take advantage of the opportunity. Beyond capital, the company received vital introductions to the medical and clinical community there. The start-up, one of more than 15 companies to have licensed rights to Medarex's HuMAb-Mouse technology, has already taken one fully human antibody into clinical trials, and hopes to put three more there in 2001. Genmab is also seeking to in-license rights to other antibodies. Given the relatively low cost and rapid development time for antibodies versus small molecules, the company thinks it can afford to manage development of multiple candidates simultaneously.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090228

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel